GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...

GSK further contends that Moderna got its hands on technical know-how tied to the company’s mRNA vaccine platform by “hiring several former Novartis and GSK employees with first-hand knowledge.” ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

GlaxoSmithKline ( (GSK)) has realeased its Q3 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors. GlaxoSmithKline (GSK) is a global biopharmaceutical ...

Welcome to today's call and webcast. The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to Slide 2. This is the usual safe harbor ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...

(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster ...